The effect of the menopause and hormone replacement therapy on serum carboxyterminal propeptide of type I collagen.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8422517.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the effect of the menopause and postmenopausal hormone replacement therapy on the serum concentration of carboxyterminal propeptide of type I procollagen (PICP), which is a biochemical marker of type I collagen synthesis. A group of 124 healthy postmenopausal women, aged 45-53 years, had about 20% higher serum PICP than did a group of 40 healthy premenopausal women aged 35-52 years (114 +/- 35 micrograms/l vs. 95 +/- 26 micrograms/l (mean +/- SD); p = 0.002). The 124 postmenopausal women were also participating in a double-masked longitudinal study with two placebo groups and four different hormone replacement therapy groups. The four hormone regimens resulted in similar responses in serum PICP. Compared with placebo, 1 year of treatment with any of the four hormone replacement therapies significantly decreased serum PICP to premenopausal levels. We conclude that the formation of type I collagen is increased shortly after the menopause and that hormone replacement therapy reverses this increase.
Medical subject headings
- Estrogen Replacement Therapy
- Menopause
- Peptide Fragments
- Procollagen